Organon (OGN) Total Current Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Total Current Liabilities of $2.6 billion for Q2 2026, down 6.44% year-over-year from $2.8 billion in Q2 2025, and up 4.64% on a QoQ basis from $2.5 billion in Q1 2026.
Organon (OGN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Organon has reported Total Current Liabilities for 7 years, with the latest figure at $2.6 billion in Q2 2026.
- Total Current Liabilities for Q2 2026 came in at $2.6 billion, down 6.44% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.6 billion (down 6.44% YoY), and the FY2025 annual result was $2.4 billion, down 12.07% from the prior year.
- Total Current Liabilities grew to $2.6 billion in Q2 2026, from $2.5 billion in the prior quarter.
- Over five years, Total Current Liabilities peaked at $2.9 billion in Q4 2023 and troughed at $2.3 billion in Q1 2022.
- A 5-year average of $2.6 billion and a median of $2.5 billion in 2022 frame the typical range for Total Current Liabilities.
- The widest annual swing landed in 2022, when Total Current Liabilities slipped 25.6%; it then gained 16.16% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $2.5 billion in 2022, then rose by 16.16% to $2.9 billion in 2023, then fell by 6.85% to $2.7 billion in 2024, then slipped by 12.07% to $2.4 billion in 2025, then rose by 9.46% to $2.6 billion in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $2.6 billion in Q2 2026, $2.5 billion in Q1 2026, and $2.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.97 Bn | 633.21 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 470.43 Bn | 463.86 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 376.87 Bn | 369.73 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.36 Bn | 295.67 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.56 Bn | 252.66 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 236.76 Bn | 222.77 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 182.01 Bn | 178.83 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.08 Bn | 101.91 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 2.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.62 Bn |
| Mar 31, 2026 | 2.50 Bn |
| Dec 31, 2025 | 2.39 Bn |
| Sep 30, 2025 | 2.68 Bn |
| Jun 30, 2025 | 2.80 Bn |
| Mar 31, 2025 | 2.62 Bn |
| Dec 31, 2024 | 2.72 Bn |
| Sep 30, 2024 | 2.79 Bn |
| Jun 30, 2024 | 2.76 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Dec 31, 2023 | 2.92 Bn |
| Sep 30, 2023 | 2.49 Bn |
| Jun 30, 2023 | 2.39 Bn |
| Mar 31, 2023 | 2.35 Bn |
| Dec 31, 2022 | 2.51 Bn |
| Sep 30, 2022 | 2.33 Bn |
| Jun 30, 2022 | 2.40 Bn |
| Mar 31, 2022 | 2.31 Bn |
| Dec 31, 2021 | 2.60 Bn |
| Sep 30, 2021 | 3.13 Bn |